Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients

a systematic review

Research output: Contribution to journalReviewResearchpeer-review

1 Downloads (Pure)

Abstract

Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.

Original languageEnglish
JournalClinical Chemistry and Laboratory Medicine
Volume56
Issue number5
Pages (from-to)688-701
ISSN1434-6621
DOIs
Publication statusPublished - 2018

Fingerprint

Epidermal Growth Factor Receptor
Blood
Ligands
Biomarkers
Publications
Oncology
Progesterone Receptors
Serum
Estrogen Receptors
Tumors

Keywords

  • Biomarkers, Tumor/antagonists & inhibitors
  • Breast Neoplasms/blood
  • ErbB Receptors/antagonists & inhibitors
  • Female
  • Humans
  • Ligands
  • Predictive Value of Tests
  • Prognosis

Cite this

@article{7fa73941cf4141949517c4fabb2139ad,
title = "Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review",
abstract = "Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.",
keywords = "Biomarkers, Tumor/antagonists & inhibitors, Breast Neoplasms/blood, ErbB Receptors/antagonists & inhibitors, Female, Humans, Ligands, Predictive Value of Tests, Prognosis",
author = "Kjaer, {Ina Mathilde} and Troels Bechmann and Ivan Brandslund and Madsen, {Jonna Skov}",
year = "2018",
doi = "10.1515/cclm-2017-0592",
language = "English",
volume = "56",
pages = "688--701",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walterde Gruyter GmbH",
number = "5",

}

TY - JOUR

T1 - Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients

T2 - a systematic review

AU - Kjaer, Ina Mathilde

AU - Bechmann, Troels

AU - Brandslund, Ivan

AU - Madsen, Jonna Skov

PY - 2018

Y1 - 2018

N2 - Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.

AB - Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.

KW - Biomarkers, Tumor/antagonists & inhibitors

KW - Breast Neoplasms/blood

KW - ErbB Receptors/antagonists & inhibitors

KW - Female

KW - Humans

KW - Ligands

KW - Predictive Value of Tests

KW - Prognosis

U2 - 10.1515/cclm-2017-0592

DO - 10.1515/cclm-2017-0592

M3 - Review

VL - 56

SP - 688

EP - 701

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 5

ER -